

Executive Summary
Collaborative Working Project Gastroenterology

Organisations involved

Royal Wolverhampton NHS Trust (New Cross Hospital) / AbbVie

Summary

This collaboration aims to raise the Standards of Care (SoC) for patients with Inflammatory Bowel Disease (IBD) by embedding Quality of Life (QoL) assessments via patient reported outcomes in routine clinical practice and demonstrating its impact on patient care, disease control and service delivery.

The project will run for 2 years starting in September 2024.

Background

The landscape in gastroenterology for IBD is changing, with many more effective treatments available. Despite these advancements, a significant number of patients have suboptimal disease control, delayed access to diagnosis and treatment, and therefore remission, significantly affecting patients QoL.

Project Objectives

- Raising SoC for patients with IBD
- Improve health outcomes and service delivery to IBD patients
- Ensure all HCPs involved in the patient journey are supported to expand their skills
- Measure impact of implementation of QoL assessments in routine clinical practice
- Disseminate outcomes and sharing of best practice

Benefits

Benefits to patients

- Improved SoC through including QoL measures in routine assessments
- Improved access through 'fast track pathway'
- Enhanced patient satisfaction

Benefits to the NHS

- Greater understanding of impact of measuring QoL in IBD
- Enhanced use of 'fast track pathway' for IBD
- Co-ordination of patient care and multidisciplinary teamwork

Benefits to AbbVie

- Demonstrated partner of choice for opportunities to improve patient standards of care
- Support AbbVie's position as leaders within the immunology landscape
- Gain better understanding of the NHS challenges to provide specialist patient care to inform further initiatives to improve standards of care

Funding and Resources

This project is a shared contribution of time between Royal Wolverhampton NHS Trust and AbbVie. Funding for meeting space, resulting meeting materials and medical writing will be provided by AbbVie.

Date of Preparation: July 2026 UK-ABBV-260242

Contact

AbbVie Ltd

AbbVie House

Vanwall Business Park

Vanwall Road

Maidenhead

Berkshire

SL6 4UB

centralisationteam@abbvie.com

This executive summary is published on: www.abbvie.co.uk